Top Markets
Coin of the day
Cyxone AB (publ) Cyxone AB (publ)

Cyxone AB (publ)

CYXO
Rank in Stocks #40403
Cyxone AB (publ) is a clinical-stage biotechnology firm focused on developing... Cyxone AB (publ) is a clinical-stage biotechnology firm focused on developing innovative, disease-modifying therapies. Its primary therapeutic targets include rheumatoid arthritis, multiple sclerosis, and acute respiratory illnesses caused by viruses. The company's pipeline features Rabeximod, currently in Phase II clinical trials for both rheumatoid arthritis and COVID-19. Additionally, T20K, a drug candidate for multiple sclerosis, is undergoing Phase 1 evaluation. Established in 2015, the company is headquartered in MalmΓΆ, Sweden.
Share Price
$0.00162013
Last synced: 2025-01-03
Market Cap
$156.25K
Change (1 day)
0.36%
Change (1 year)
0.00%
Country
SE
Trade Cyxone AB (publ) (CYXO)

Category

P/S ratio for Cyxone AB (publ) (CYXO)
P/S ratio as of August 2026 TTM: 1.31
According to Cyxone AB (publ) latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 1.31. At the end of 2022 the company had a P/S ratio of 6.98.
P/S ratio history for Cyxone AB (publ) from 2015 to 2026
P/S ratio at the end of each year
Year P/S Ratio Change
2026 (TTM) 1.31 -30.24%
2023 1.88 -72.98%
2022 6.98 0.00%
2021 0.00 0.00%
2020 0.00 -100.00%
2019 6.23K -93.33%
2018 93.45K 0.00%
2017 0.00 -100.00%
2016 4.88K 24.54%
2015 3.92K 0.00%
P/S ratio for similar companies or competitors
Company P/S Ratio P/S Ratio Difference Country
9.88 653.45%
US
10.30 685.65%
NL
- -
CH
- -
KR
4.98 279.69%
BE